| アブストラクト | BACKGROUND: Real-world data assessing characteristics of patients with asthma initiating inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta(2)-agonist (ICS/LAMA/LABA) triple therapy in Japan are limited. METHODS: Descriptive, observational study of patients with asthma aged >/=15 years newly initiating single- or multiple-inhaler triple therapy (SITT: fluticasone furoate/umeclidinium/vilanterol [FF/UMEC/VI], SITT: indacaterol/glycopyrronium bromide/mometasone furoate [IND/GLY/MF] or MITT) or ICS/LABA using JMDC/Medical Data Vision (MDV) health insurance databases from February 2021-February 2022 (first prescription date: index date). Patients were assigned to three non-mutually exclusive cohorts: A) new FF/UMEC/VI initiators; B) new FF/UMEC/VI, IND/GLY/MF, or MITT initiators; C) new FF/UMEC/VI, IND/GLY/MF, MITT or ICS/LABA initiators as initial maintenance therapy (IMT). Patient characteristics were assessed descriptively for 12-months pre-treatment initiation (baseline period). RESULTS: Cohort A: among new FF/UMEC/VI initiators, 12.8% and 0.1% (JMDC) and 21.7% and 0.9% (MDV) of patients had >/=1 moderate and severe exacerbation; 52.0% (JMDC) and 79.2% (MDV) had ICS/LABA use. Cohort B: most patients initiated FF/UMEC/VI and IND/GLY/MF over MITT (JMDC: 91.3% vs 8.7%; MDV: 67.8% vs 32.2%), with fewer exacerbations and lower rescue medication use. Cohort C: a greater proportion of FF/UMEC/VI initiators as IMT experienced a moderate exacerbation at index versus ICS/LABA initiators as IMT (JMDC: 17.8% vs 10.7%; MDV: 8.0% vs 5.1%). CONCLUSIONS: Patient characteristics were generally similar between treatment groups; SITT initiators had fewer exacerbations and lower rescue medication use than MITT initiators, represented by the greater proportion of IMT among SITT versus MITT initiators. Physicians may have prescribed triple over dual therapy as IMT in response to an exacerbation. |
|---|
| 投稿者 | Oga, Toru; Mita, Chifuku; Ito, Risako; Requena, Gema; Rothnie, Kieran J; Noorduyn, Stephen G; Yuanita, Liza; Yarita, Masao |
|---|
| 組織名 | Department of Respiratory Medicine, Kawasaki Medical School, 577, Matsushima,;Kurashiki, Okayama, 701-0192, Japan. Electronic address:;ogato@med.kawasaki-m.ac.jp.;Value Evidence and Outcomes, Japan Medical and Development, GSK, 1-8-1 Akasaka,;Minato-ku, Tokyo 107-0052, Japan.;Global Value Evidence and Outcomes, Epidemiology, GSK, 980 Great West Rd,;Brentford, Middlesex, TW8 9GS, UK.;Value Evidence and Outcomes, 100 Milverton Drive, Suite 800, Mississauga,;Ontario, L5R 4H1, Canada; Department of Health Research Methods, Evidence, and;Impact, McMaster University, 1280 Main St W, Hamilton, Ontario, L8S 4L8, Canada.;Medical Affairs Asthma & COPD, Japan Medical and Development, GSK, 1-8-1 Akasaka, |
|---|
